Phio Pharmaceuticals to present corporate and clinical update at Life Sciences Future 2025

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL^® siRNA gene silencing technology to eliminate cancer. Phio announced that Phio Pharmaceuticals is a presenting company at the Life Sciences Future Conference to be held September 25 – 26, 2025.

Mr. Robert Bitterman, President and CEO of Phio Pharmaceuticals, will deliver an update on its on-going Phase 1b clinical trial for skin cancer. He will also be discussing strategy and anticipated next steps in the PH-762 development program upon completion of the treatment phase of the study. Mr. Bitterman and his management team will also be available for one-on-one meetings throughout the conference September 25 – 26, 2025.

Presentation Details: September 26, 2025 at 10:00 AM EST
Location: Life Sciences Future Conference, Sheraton Valley Forge Hotel, King of Prussia, PA

Life Sciences Future is the annual meeting of the Pennsylvania life sciences community hosted by Life Sciences PA (formerly Pennsylvania Bio). Key stakeholders including pharmaceutical companies, research institutions, investment organizations and strategic advisors are invited to participate in the September meeting in King of Prussia, PA